Brainstorm Cell Therapeutics, Inc. (BCLI)
0.9302
-0.07
(-6.98%)
USD |
OTCM |
Oct 02, 16:00
Brainstorm Cell Therapeutics EPS Diluted (Quarterly) : -0.3494 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3494 |
| March 31, 2026 | -0.1928 |
| December 31, 2025 | -0.2206 |
| September 30, 2025 | -0.1913 |
| June 30, 2025 | -0.3368 |
| March 31, 2025 | -0.4516 |
| December 31, 2024 | -0.4841 |
| September 30, 2024 | -0.51 |
| June 30, 2024 | -0.5352 |
| March 31, 2024 | -0.788 |
| December 31, 2023 | -1.659 |
| September 30, 2023 | -0.4156 |
| June 30, 2023 | -2.014 |
| March 31, 2023 | -2.066 |
| December 31, 2022 | -2.054 |
| September 30, 2022 | -2.819 |
| June 30, 2022 | -2.895 |
| March 31, 2022 | -2.206 |
| December 31, 2021 | -2.558 |
| September 30, 2021 | -2.205 |
| June 30, 2021 | -2.589 |
| March 31, 2021 | -2.792 |
| December 31, 2020 | -5.534 |
| September 30, 2020 | -2.161 |
| June 30, 2020 | -3.789 |
| Date | Value |
|---|---|
| March 31, 2020 | -4.282 |
| December 31, 2019 | -4.979 |
| September 30, 2019 | -3.797 |
| June 30, 2019 | -3.387 |
| March 31, 2019 | -3.605 |
| December 31, 2018 | -3.890 |
| September 30, 2018 | -2.25 |
| June 30, 2018 | -2.40 |
| March 31, 2018 | -1.80 |
| December 31, 2017 | 0.2181 |
| September 30, 2017 | -1.95 |
| June 30, 2017 | -0.90 |
| March 31, 2017 | -1.50 |
| December 31, 2016 | -0.5008 |
| September 30, 2016 | -1.35 |
| June 30, 2016 | -0.75 |
| March 31, 2016 | -1.50 |
| December 31, 2015 | -1.05 |
| September 30, 2015 | -2.10 |
| June 30, 2015 | -1.80 |
| March 31, 2015 | -1.80 |
| December 31, 2014 | -2.70 |
| September 30, 2014 | -2.40 |
| June 30, 2014 | -2.25 |
| March 31, 2014 | -2.25 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0017 |
| Summit Therapeutics, Inc. | -0.2772 |
| Kezar Life Sciences, Inc. | -0.7838 |
| Protara Therapeutics, Inc. | -0.3552 |
| Clene, Inc. | -1.084 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.855M |
| Total Expenses (Quarterly) | 3.855M |
| Enterprise Value | 11.62M |
| Earnings Yield | -102.6% |
| Normalized Earnings Yield | -102.56 |